Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
 Marie Luise Hütter-Krönke: Can a Short Course of BCMA-Targeted Therapy Induce Long-Term Remission in Refractory Autoimmune Disease?
 Marie Luise Hütter-Krönke/LinkedIn
Jul 5, 2026, 02:45

 Marie Luise Hütter-Krönke: Can a Short Course of BCMA-Targeted Therapy Induce Long-Term Remission in Refractory Autoimmune Disease?

 Marie Luise Hütter-Krönke, Senior Physician in Hematology and Oncology at Charité – Universitätsmedizin Berlin, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Blood Immunology and Cellular Therapy, adding:

“Can a short course of BCMA-targeted therapy induce long-term remission in refractory autoimmune disease?

I am delighted to share our latest publication, reporting three patients with severe, multiply refractory immune thrombocytopenia (ITP) who achieved rapid and sustained treatment-free remission following therapy with the BCMA×CD3 bispecific antibody teclistamab.

For ITP patients who have exhausted multiple treatment options, durable remissions remain one of the greatest unmet needs. Seeing these patients recover—and remain off therapy—has been incredibly rewarding for our entire team.

Our key findings:

  • Rapid platelet recovery within 4, 9 and 23 days.
  • Discontinuation of corticosteroids and all other ITP-directed therapies.
  • Sustained treatment-free remission for up to 9 months of follow-up.
  • Resolution of autoimmune hemolytic anemia in the Evans syndrome patient.
  • Favorable safety profile with manageable adverse events.

Although this is an early proof-of-concept case series, these observations support the hypothesis that targeting BCMA-positive long-lived plasma cells may represent a promising therapeutic strategy for severe autoimmune cytopenias and warrant prospective clinical investigation.

This work would not have been possible without an outstanding multidisciplinary collaboration.”

Title: BCMA-targeted T-cell engager therapy induces sustained remission in immune thrombocytopenia

Authors: Michael Korenkov, Maximilian Rudolf Zuleeg, Julian Liebaert, Vincent Fregona, Sebastian Serve, Julia Jesse, David Böckle, Stephan Rainer Bohl, Frederik Damm, Lars Bullinger, Ulrich Keller, Antonia Busse, Adrian Schwarzer, Fredrik Albach, Thomas Thiele, Simon Haas, Jan Krönke, Marie Luise Hütter-Krönke Marie Luise Hütter-Krönke: Can a Short Course of BCMA-Targeted Therapy Induce Long-Term Remission in Refractory Autoimmune Disease?

Stay updated on all scientific advances with Hemostasis Today.

 

Adrian Schwarzer Antonia Busse David Böckle Frederik Damm Fredrik Albach Health Hematology Hemostasis News Hemostasis Today Jan Krönke Julia Jesse Julian Liebaert Lars Bullinger Marie Luise Hütter-Krönke Maximilian Rudolf Zuleeg Michael Korenkov Sebastian Serve Simon Haas Stephan Rainer Bohl Thomas Thiele thrombocytopenia Ulrich Keller Vincent Fregona
NewsFeed